Tuesday
SESSION 5: NEW KEY DEVELOPMENTS IN THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE
SESSION 5 SCHEDULE
1:00 PM - 1:05 PM Endovascular Repair Of Saccular Aneurysms Of The Extracranial Internal Carotid Artery Is No Longer Hazardous But Fusiform Aneurysms Remain A Challenge: Tips And Tricks: Long-Term Results
  Presenter(s):James May, MD, MS, FRACS, FACS  
  View Slides in PDF      
1:06 PM - 1:11 PM Value Of OCT And IVUS Evaluation Before And After CAS: How Can They Improve Results
  Presenter(s):Carlo Setacci, MD / Bernhard Reimers, MD  
  View Slides in PDF      
1:12 PM - 1:17 PM Optimal Medical Management To Decrease Cardiovascular And Stroke Risk As In The SAMMPRIS Trial: It Is Not Simple And Requires Training: How To Do It And What Are The Treatment Goals
  Presenter(s):Colin P. Derdeyn, MD  
  View Slides in PDF      
1:18 PM - 1:23 PM Despite Level 1 Evidence To The Contrary, Patches Are Not Always Necessary With CEA And Patches Can Cause Serious Complications: How To Avoid Patch Closures
  Presenter(s):Robert B. McLafferty, MD  
  View Slides in PDF      
1:24 PM - 1:29 PM With High-Grade Asymptomatic Carotid Stenosis (ACS) There Is A Low Rate Of Occlusion And Stroke In Patients On Current Best Medical Therapy (BMT)
  Presenter(s):J. David Spence, MD  
  View Slides in PDF      
1:30 PM - 1:35 PM DEBATE: The 10-Year CREST Trial Results Indicate That CAS Is Equivalent To CEA In Both Symptomatic And Asymptomatic Carotid Stenosis Patients
  Presenter(s):Thomas G. Brott, MD / Brajesh K. Lal, MD  
  View Slides in PDF      
1:36 PM - 1:41 PM DEBATE: Not So Fast: There Are Other Ways To Interpret The 10-Year Results From CREST
  Presenter(s):J. David Spence, MD  
  View Slides in PDF      
1:42 PM - 1:47 PM How Best To Manage Acute Carotid Occlusion After CEA: Why Endovascular Treatment Can Be The Best Option
  Presenter(s):Alejandro M. Spiotta, MD  
  View Slides in PDF      
1:48 PM - 1:54 PM Panel Discussion
Moderator(s): Claudio J. Schonholz, MD / L. Nelson Hopkins, MD  
1:54 PM - 1:59 PM DEBATE: 5-Year Results From The ACT-1 Trial Show That CAS Is Equivalent To CEA For Asymptomatic Carotid Stenosis (ACS)
  Presenter(s):Kenneth Rosenfield, MD / Jon S. Matsumura, MD  
  View Slides in PDF      
2:00 PM - 2:05 PM DEBATE:Not So Fast: There Is Another Interpretation To ACT-1: It Does Not Change Current Evidence That BMT Alone Is Best For Asymptomatic Carotid Stenosis
  Presenter(s):Anne L. Abbott, MD, PhD, FRACP  
  View Slides in PDF      
2:06 PM - 2:11 PM Systemic Biomarkers Can Predict The Stroke Risk Of Carotid Plaques And Cognitive Decline After CEA And CAS: Are There Differences Between The 2 Procedures
  Presenter(s):Wei Zhou, MD  
  View Slides in PDF      
2:12 PM - 2:17 PM DEBATE: How To Identify Those ACS Patients Who Can Benefit From An Invasive Intervention (CEA Or CAS): What Is That Percentage Of ACS Patients
  Presenter(s):Andrew N. Nicolaides, MS, FRCS  
  View Slides in PDF      
2:18 PM - 2:23 PM DEBATE: The Rationale For A Differing Viewpoint: What Percentage Of ACS Patients Should Be Treated Invasively And Why CEA Is The Best Treatment
  Presenter(s):Bruce A. Perler, MD, MBA  
  View Slides in PDF      
2:24 PM - 2:29 PM In Light Of The 10-Year CREST Results And The 5-Year ACT-1 Results, How Should We Regard The Future Of CAS For Symptomatic And Asymptomatic Carotid Stenosis Patients: A UK And European Perspective
  Presenter(s):Ross Naylor, MD, FRCS  
  View Slides in PDF      
2:30 PM - 2:35 PM In Light Of The 10-Year CREST And 5-Year ACT-1 Results How Should We Regard The Future Of CAS For Symptomatic And Asymptomatic Carotid Stenosis: A US Perspective
  Presenter(s):Jon S. Matsumura, MD  
  View Slides in PDF      
2:36 PM - 2:42 PM Panel Discussion
2:42 PM - 2:55 PM Break Visit Exhibits And Pavilions (2nd and 3rd Floors)
END OF SESSION 5
previous next